The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL Multi-center, randomized study designed to assess the efficacy, ...

Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive results from the Phase 2 SUMIT-BC clinical ...

Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and ...

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Initial data from a phase 2 (NCT05256290) clinical trial show that silevertinib yields robust antitumor activity and ...

GLP-1 drug could offset metabolic risks of second-generation antipsychotics ...

By Dr. Liji Thomas, MD By pairing late-pregnancy risk screening with personalised timing of birth, researchers show how term ...

"With LumosityRx, we're taking the core science and technology behind Lumosity and applying it to help people with ADHD, where attention is crucial to everyday life," said Dr. Bob Schafer, ...